Senators press Mylan Labs over ‘outrageous’ EpiPen pricing

(By Ed Silverman for STAT)

Move over, Martin Shkreli. Get in line, Valeant Pharmaceuticals. Congress appears to have found another drug maker to scold over high prices. Continue reading article here……

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.